Neurocrine Biosciences Inc (NBIX)

Total asset turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	1,882,900	1,779,300	1,668,300	1,522,900	1,411,600	1,306,100	1,208,800	1,185,500	1,107,700	1,050,200	1,010,800	1,022,200	1,020,900	1,017,010	981,066	862,604	764,254	651,736	581,765	503,032
Total assets	US$ in thousands	3,251,400	2,848,200	2,613,100	2,359,800	2,368,700	2,143,400	2,005,700	2,144,500	2,072,500	2,017,300	1,956,400	1,846,400	1,734,700	1,502,600	1,515,600	1,361,900	1,306,000	1,179,940	1,066,860	957,723
Total asset turnover		0.58	0.62	0.64	0.65	0.60	0.61	0.60	0.55	0.53	0.52	0.52	0.55	0.59	0.68	0.65	0.63	0.59	0.55	0.55	0.53

December 31, 2023 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $1,882,900K ÷ $3,251,400K
= 0.58

The total asset turnover ratio for Neurocrine Biosciences, Inc. has shown some fluctuation over the past eight quarters, ranging from 0.56 to 0.68. This ratio indicates the company's efficiency in generating revenue from its total assets.

A downward trend in total asset turnover may suggest that Neurocrine Biosciences, Inc. is becoming less efficient in utilizing its assets to generate sales, which could be a cause for concern. However, the ratio has shown some variability over time, indicating that the company's performance in this area may be influenced by various factors.

It is important for investors and stakeholders to monitor this ratio over time to assess the company's ability to effectively manage its assets and generate sales. Further analysis and comparison with industry benchmarks or competitors' ratios would provide additional insights into Neurocrine Biosciences, Inc.'s asset utilization efficiency.